Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 12/20 | 0.44 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374261 | 0.84 | HRH1 (0.38) | HRH1FERMT2HRH3HRH4MEN1 | |
| SCHEMBL11814507 | 0.79 | HRH1 (0.46) | HRH1HRH3HRH2 | |
| SCHEMBL1444830 | 0.79 | KCNH2 (0.41) | CYP3A4 | |
| SCHEMBL15057849 | 0.77 | GABRA2 (0.38) | MEN1CYP1A2CYP3A4CYP2D6KMT2A | |
| SCHEMBL374273 | 0.76 | — | — | |
| SCHEMBL7995943 | 0.73 | CYP1A2 (0.36) | FERMT2MEN1CYP1A2CYP2D6KMT2A | |
| SCHEMBL16033555 | 0.72 | KDM4E (0.42) | MEN1CYP3A4KMT2A | |
| SCHEMBL15891880 | 0.72 | RECQL (0.36) | MEN1KMT2A | |
| SCHEMBL30756402 | 0.68 | ENPP1 (0.33) | — | |
| SCHEMBL11813336 | 0.68 | HRH1 (0.59) | HRH1HRH3HRH2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | disclosed |
| US-8084457-B2 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | LEAD DISCOVERY CENTER GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | DAPK1, DUSP4, MARK4 | HRH1 4637/4885FERMT2 2298/4885HRH3 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.